Case series reports skin blisters in diabetes patients using vildagliptin, suggesting rare side effects.
Vildagliptin, among the most commonly used, OHA, belongs to group dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus, has recently been associated with bullous pemphigoid, characterized by fluid-filled blisters and erosions on the skin and mucous membranes. We report the series of three cases of bullous pemphigoid in patients of diabetes, who developed bullous pemphigoid after vildagliptin use.
No takes yet. Share an insight, caveat, or question.
Shahi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: